The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BTX | -86.86% | -99.88% | -73.95% | -100% |
| S&P | +12.26% | +86.71% | +13.3% | +67% |
Eterna Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.
The biotech is bulking up with a new acquisition.
This clinical-stage biotech was one of April's brightest stars.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.07M | -172.9% |
| Gross Margin | -6700.00% | -3582.4% |
| Market Cap | $8.40M | 47.8% |
| Market Cap / Employee | $1.40M | 0.0% |
| Employees | 6 | -25.0% |
| Net Income | -$1.24M | 95.3% |
| EBITDA | -$1.92M | 43.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.05M | -28.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.35M | -98.9% |
| Short Term Debt | $0.21M | -96.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -264.07% | -114.2% |
| Return On Invested Capital | -489.37% | -403.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.29M | 79.5% |
| Operating Free Cash Flow | -$1.27M | 79.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.89 | -1.56 | -1.08 | 1.84 | -1573.00% |
| Price to Sales | 25.96 | 17.75 | 19.53 | 9007.47 | 94723.82% |
| Price to Tangible Book Value | -0.50 | -398.84 | -0.80 | 3.42 | -290.12% |
| Enterprise Value to EBITDA | -5.35 | -3.93 | -2.37 | -3.39 | -71.27% |
| Return on Equity | -302.2% | -1154.2% | -2264.3% | - | |
| Total Debt | $0.68M | $2.88M | $0.59M | $0.55M | -98.57% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
